UNIVERSITI TEKNOLOGI MARA

EVALUATION TIME IN THERAPEUTIC RANGE (TTR) OF PATIENT IN WARFARIN MEDICATION THERAPY ADHERENCE CLINIC (MTAC) IN HOSPITAL PUTRAJAYA

NOOR FADZILLAH ARIFFIN

Dissertation submitted in partial fulfillment of the requirements for the degree of Master of Clinical Pharmacy

FACULTY OF PHARMACY

January 2016
I certify that a Panel of Examiners has met on 21st January 2016 to conduct the final examination of Noor Fadzillah Ariffin on her Master of Clinical Pharmacy thesis entitled “Evaluation Time In Therapeutic Range (TTR) Of Patient In Warfarin Medication Therapy Adherence Clinic (MTAC) In Hospital Putrajaya” in accordance with Universiti Teknologi MARA Act 1976 (Akta 173). The Panel of Examiners recommends that the student be awarded the relevant degree. The panel of Examiners was as follows:

Noorizan Abd Aziz, PhD
Professor
Faculty of Pharmacy
Universiti Teknologi MARA
(Supervisor)

Yahaya Hassan, PhD
Professor
Faculty of Pharmacy
Universiti Teknologi MARA
(Co-Supervisor)

Long Chiau Ming, PhD
Senior lecturer
Faculty of Pharmacy
Universiti Teknologi MARA
(Internal Examiner)

Khairil Anuar Md Isa
Lecturer
Faculty of Health Science
Universiti Teknologi MARA
(External Examiner)

AISHAH ADAM, PhD
Professor
Dean
Faculty of Pharmacy
University Teknologi MARA
AUTHOR’S DECLARATION

I declare that the work in this thesis/dissertation was carried out in accordance with the regulations of Universiti Teknologi MARA. It is original and is the results of my own work, unless otherwise indicated or acknowledged as referenced work. This thesis has not been submitted to any other academic institution or non-academic institution for any degree or qualification.

I, hereby, acknowledge that I have been supplied with the Academic Rules and Regulations for Post Graduate, Universiti Teknologi MARA, regulating the conduct of my study and research.

Name of Student : Noor Fadzillah Ariffin
Student I.D. No. : 2014460096
Programme : Master of Clinical Pharmacy
Faculty : Pharmacy
Dissertation Title : Evaluation Time in Therapeutic Range (TTR) Of Patient in Warfarin Medication Therapy Adherence Clinic (MTAC) in Hospital Putrajaya
Signature of Student : ………………………………………
Date : January 2016
ABSTRACT

Background: Warfarin is the most commonly used oral anticoagulant and has a narrow therapeutic window therefore requires frequent monitoring to maintain the desired treatment targets. Time in therapeutic range (TTR) usually use to identify the quality of INR control in patient with oral anticoagulant. We examined the status of and factor influence TTR and also bleeding and thromboembolic event in warfarin MTAC patients. Methods: We enrolled 162 patients from warfarin MTAC patients list. Patient’s data were accessed retrospectively through electronic medical records. TTR was calculated using the linear interpolation technique. Descriptive data were analysed using frequency and percentage. Simple logistic regression was used for univariate analyses. Result: The mean of the individual’s TTR calculated by using the Rosendaal method was 76%, (SD 18.5%) and only 24% of the INR value was out of the target range. Overall percentage of bleeding event would be 11.7% and percentage of thromboembolic events was only around 0.6%. Overall out of 162 patients, 135 patients show the TTR value is more than 60% and only 27 patients the TTR value less than 60%. TTR was not affected by age, gender, sex, race, indications, duration of warfarin, weekly dose and number of concurrent medication. Missed dose was the only statistical significant predictor of poor TTR value (P < 0.001). In patient with missed dose of warfarin has a 2.2 times more likely of having TTR value less than 60% with 95% confident interval (1.50 to 3.12). Conclusion: TTR is generally high in pharmacist managed clinic patients. The INR value most of time was spent within the target ranges. Thus, reflecting a good INR control in pharmacist managed clinic. Keywords: Anticoagulant, TTR, pharmacist-managed clinic
# TABLE OF CONTENTS

AUTHOR’S DECLARATION ........................................................................................................ iii
ABSTRACT ................................................................................................................................. iv
ACKNOWLEDGEMENT ............................................................................................................... v
LIST OF FIGURES .................................................................................................................... ix
LIST OF TABLES ........................................................................................................................ x
LIST OF ABBREVIATIONS ........................................................................................................ xi

## CHAPTER ONE: INTRODUCTION ......................................................................................... 1
  1.1 BACKGROUND ................................................................................................................... 1
  1.2 PROBLEM STATEMENT .................................................................................................... 2
  1.3 RESEARCH OBJECTIVES ............................................................................................... 3
  1.4 RESEARCH QUESTIONS ................................................................................................. 3
  1.5 SCOPE AND LIMITATION OF THE STUDY .................................................................. 3
  1.6 SIGNIFICANCE OF THE STUDY ..................................................................................... 3

## CHAPTER TWO: LITERATURE REVIEW ............................................................................ 4
  2.1 OVERVIEW OF WARFARIN ............................................................................................. 4
  2.2 PHARMACOLOGY OF WARFARIN .................................................................................. 5
    2.2.1 Mechanism of Action ............................................................................................. 5
    2.2.2 Pharmacokinetics and Pharmacodynamics ............................................................ 6
  2.3 INTERNATIONAL NORMALISED RATIO (INR) ............................................................... 7
    2.3.1 Factors that Influence the Effect of Warfarin .......................................................... 8
  2.4 TIME IN THE THERAPEUTIC RANGE (TTR) ................................................................. 16
  2.5 BLEEDING AND THROMBOEMBOLIC EVENT .............................................................. 19
  2.6 MEDICATION THERAPY ADHERENCE CLINIC (MTAC) SERVICES ... 21